Science Links Japan | Clinical Evaluation of Proton Pump Inhibitor, Rabeprazole. Special Surveillance in Patients of Advanced Age with Peptic Ulcer Diseases.

Clinical Evaluation of Proton Pump Inhibitor, Rabeprazole. Special Surveillance in Patients of Advanced Age with Peptic Ulcer Diseases.

Accession number;02A0682521

Title;Clinical Evaluation of Proton Pump Inhibitor, Rabeprazole. Special Surveillance in Patients of Advanced Age with Peptic Ulcer Diseases.

Author;FUJITA RIKIYA(Showa Univ., Fujigaoka Hospital) HARA HISATO(Hakushokai Sanobyoin Shokakika) KOYAMA TSUNEO(Nagano Prefect. Welf. Fed. of Agric. Coop. Saku Cent. Hosp.) MINE TETSUYA(Univ. Tokyo, Univ. Branch Hospital) SUZUKI HIDEKAZU(Keio Univ.) OBA KEN'ICHI(Nagoya City Higashi Munic. Hosp.) NAGAO TOSHIHIRO(Sogodaiyukaibyoin Shokakika) SHIBATA YOKO(Takamatsu Municipal Hospital, JPN) SHIMAJIRI HIROTO(Nahashibyoin Naika)

Journal Title;Japanese Pharmacology & Therapeutics

Journal Code:Z0947A

ISSN:0386-3603

VOL.30;NO.7;PAGE.539-549(2002)

Figure&Table&Reference;TBL.10, REF.20

Pub. Country;Japan

Language;Japanese

Abstract;We surveyed the safety and efficacy of rabeprazole (Pariet tablet) in patients of advanced age (.GEQ.65 years old) undergoing treatment of gastric ulcer, duodenal ulcer, stomal ulcer, reflux esophagitis and Zollinger-Ellison syndrome. A total of 124 patients were enrolled in this surveillance, with 102 being eligible for safety assessment and 98 for efficacy assessment. Seven adverse reactions were reported in 5 patients. The incidence of adverse reactions was 4.90%. All adverse reactions were mild or moderate, and no severe adverse reactions was observed. Statistical analysis of the background factors of patients in the incidence of adverse reaction revealed significant differences (p<0.05) in the presence of hepatic dysfunction and the duration of administration. The endoscopic healing rates were 88.4% for gastric ulcer, 75.0% for duodenal ulcer, 100% for a stomal ulcer, 40.0% for reflux-esophagitis. The symptom disappearance rates were 94.4% for epigastric pain, 95.0% for heartburn. Concerning the global improvement, the percentage of patients judged as "improved" was 87.8%. (author abst.)